Omply Health Share Issue 11.12.2025 – 31.3.2026
A billion euro problem
Doctor shortages, long distances, or simply not being able to get an appointment when it is actually needed are all part of a healthcare crisis that calls for a fundamentally new kind of solution.
Platform first
Omply is the first platform that combines an intuitive mobile application with smart diagnostic devices that transform a smartphone into a doctor’s office.
Ready to scale
This unique combination is ready to take healthcare into a new era within a multibillion dollar market.
Greetings!
Steve Jobs once said that the greatest innovations are the ones that feel obvious only in hindsight. Omply represents exactly this kind of moment in healthcare.
Omply is a mobile-based remote doctor service that enables a physician to perform a real clinical examination remotely. The service works anywhere a smartphone works and makes it possible to listen to heart, lung, and bowel sounds; examine ears and skin; and measure blood pressure, pulse, oxygen saturation, temperature, and respiratory function. This is not just a video call — it is a real doctor’s appointment from your own home.
The technology is ready, Finland’s home pilot has been completed with excellent results, the devices are certified, and the ecosystem is built to be device-agnostic, including wearable sensors and home-use measuring devices. When the doctor is in your pocket, healthcare is no longer a system. It is an experience that happens exactly when a person needs it.
We have decided to reward all investors in this round by giving them a complete device package. This package, valued at approximately EUR 500, gives your family the opportunity to experience what modern, at-home healthcare truly feels like in practice. This is our way of thanking you for being part of Omply’s journey.
We are targeting a EUR 1 billion exit valuation within the next five years. We already have 41 committed shareholders, and we are on a path that will transform healthcare in Finland and internationally.
On this page we have compiled the key information relevant to your investment decision: our strategy, objectives, market analysis, use cases, financial figures, and our progress in Finland and globally. If you would like more information, please contact us.
Johannes Nikkanen
Chairman of the Board, Omply Health Oy
Email: johannes.nikkanen@omply.com
Tel: +358 40 517 3022
1,5-2,5M €
Target amount to be raised
1 mrd €
EXIT-valuation
in 5 years
Materials
Help users understand what matters now, and what to do next.
Omply Health Oy Share Issue Key Information Document
contains essential information about the issuer, Omply Health Oy, and the new shares. Reviewing this document is recommended so that you can make an informed investment decision. This key information document was published on 2 December 2025 and remains valid until the end of the share subscription period (PDF 0.2 MB).
Omply Pitchdeck
presents the service, market size, growth opportunities, competitive landscape, business model, technology, the principles of remote diagnostics, and exit potential. The deck provides a concise overview of how Omply transforms access to healthcare services and builds a scalable, international business (PDF 8.2 MB).
Omply Investor Memorandum
brings together the Company’s business, strategy, and financial overview. It includes a description of the market, customers, product and technology, competitive landscape, business model, as well as the Company’s current status and growth plans. The memorandum also presents the team, regulatory aspects and risk factors, the funding need, the use of proceeds and objectives, the basis for the Company’s valuation, and exit scenarios. The document provides investors with a solid foundation to assess the Company’s potential and make an investment decision (PDF 4.5 MB).
Omply Health Home-Pilot Interim Report
includes a description of the pilot and its key findings. For the first time in the world, the pilot demonstrated in practice that the technology works in a household environment and enables remote diagnostics performed by a doctor directly and seamlessly from people’s own homes. Several significant health findings were made during the pilot, highlighting the real impact and necessity of the service. The remote consultations were conducted by physicians from Solo Health Oy and Lähilääkärit Oy (PDF 0.6 MB).
The Omply Growth Plan
provides a detailed description of the Company’s growth strategy. The plan includes the timeline, key stages of technology and product launches, regulatory and quality assurance processes, market entry, team expansion, operational capacities, and monthly and annual objectives. This comprehensive roadmap offers a clear view of how the business will scale and operate internationally — and how the €1 billion exit valuation will be achieved (PDF 1.3 MB).
Protection of business operations
Help users understand what matters now, and what to do next.
Omply Patent Application
Omply has filed an extensive patent application to protect its technology. The application covers key technical solutions related to remote diagnostics, which differentiate Omply in the market. The PRH filing provides a priority period during which the patent applications can be expanded to other markets in accordance with international procedures. This strengthens the Company’s competitive position, protects its unique technology, and enables strategic patenting globally (PDF 0.1 MB).
Omply Registered Trademark
EUIPO has granted Omply a registered trademark covering both the Omply logo and its associated slogan. The registration strengthens the legal protection of the Omply brand across all EU territories and supports the Company’s international expansion. It provides clear and official protection for both the visual identity and the communication identifier, ensuring that Omply’s brand can be built consistently and securely in all future markets.
Omply ISO27001
process has been scheduled. A strong foundation for this work comes from the fact that 73Health has already achieved this certification. Since the companies share the same ownership structure, expert resources, and largely the same technological environment, Omply can build its own certification on top of an already audited and proven information security framework. This accelerates the process and provides a solid basis for meeting international requirements (PDF 0.3 MB).
Omply’s Chairman of the Board and CEO share their message with investors and explain why now is the right moment to join the journey. Omply brings remote medical diagnostics directly into the home in a way that has never been possible before. Finland’s household pilot has demonstrated that the model works both technically and clinically. Investors can join a company that is entering a rapidly scalable phase and has the potential to become a significant player in global remote healthcare (Vimeo video).
Omply’s Product Manager presents (in Finnish) the entire operational model of Omply. The walkthrough demonstrates how a user starts a remote consultation from home and how the doctor’s examination progresses in real time. The presentation covers the medical devices included in the service and how they are used at home, as well as how measurements and examination data are transmitted to the doctor. The Product Manager shows how the doctor views the patient’s information, guides the examination, and makes clinical assessments just as they would during a physical appointment. The purpose of the video is to provide a concrete, comprehensive overview of how Omply enables true remote diagnostics and brings a doctor’s expertise directly into the home (Vimeo video).
Watch in 3 minutes what Omply is all about!
Successful strategy execution
mply is progressing strongly in line with its growth strategy. In 2025, we carried out the first large-scale household pilot in Finland — and simultaneously the first of its kind in the world. The results demonstrated that clinically demanding remote diagnostics can be performed in ordinary homes using only a smartphone and selected medical devices. The pilot reached approximately 200 individuals and provided the first practical validation of Omply’s consumer-focused remote diagnostics model.
The service has been designed from the ground up for households and represents a completely new category in telehealth: real-time guided clinical examination, in which a doctor performs the actual clinical assessment remotely. No equivalent service is currently available anywhere else in the world.
The technology has been developed entirely in-house. During 2025, we validated the essential elements of the service: a home-compatible examination model, a device-agnostic architecture, and the complete process required for real-time remote examinations. Omply is built on the same technical and information security foundation as 73Health, strengthening its reliability and scalability. Significant public funding — including EU programs, ELY Centres, the Nordic Council of Ministers, the European Investment Bank, and the Ministry for Foreign Affairs of Finland — has enabled rapid development.
Funding need
We aim to accelerate our growth. The purpose of the capital raised through this share issue is to enable Omply’s commercial breakthrough and the controlled transition from the pilot phase to internationally scalable operations.
Funds will be allocated to the Finnish market launch, where Omply will be introduced to a broad group of users and doctors. The launch will also act as a reference and learning platform for future markets.
In parallel, pilot projects will be initiated in 1–2 new countries, with the purpose of adapting the operational model to local healthcare systems and preparing for market entry. These pilots help strengthen international positioning and build competitive advantage in markets where no comparable service currently exists.
A portion of the funds will be directed to continued technology development. Key areas include application usability, automation of the diagnostic process, platform independence, and device integrations. Technical and operational maturity of the platform is essential for effective commercial scaling.
Strengthening the supply chain and device procurement is a critical part of the overall plan. Omply represents high-quality medical devices delivered to households, making supply chain reliability, partner-network development, and advance procurement essential investment areas.
Team expansion and operational scaling are necessary to bring the service to market as planned. This includes growing the doctor and nurse network, strengthening customer support, and adding technical and operational personnel.
Additionally, funds will be allocated to regulatory and certification processes.
Vast global markets
The global telehealth market is valued at EUR 224.87 billion (Bloomberg, Exclusive Report on Telemedicine Industry 2023). Omply enters this market with a solution that is fundamentally different from all existing services. In traditional telemedicine, clinical examination is not possible. With Omply, doctor-guided clinical assessment can be performed remotely and directly from the patient’s home. Underlying this is a data-processing and interpretation layer, which will support future AI functionalities. Together, these create a competitive advantage in markets where no comparable end-to-end solution exists today.
We have already demonstrated our team’s capability and the practical functionality of the model through pilot projects. Omply is ready to enter the replication phase and capture market share rapidly and in a controlled manner.
Scalable SaaS business model
Omply has been designed from the outset to scale quickly and cost-effectively in Finland and internationally. The platform architecture, operating model, and device-agnostic design make it possible to deploy Omply in new markets without heavy infrastructure changes or local technical integrations.
Scalability is further supported by the fact that Omply is not tied to any single device manufacturer. Households can be equipped with medical devices from various suppliers, as long as they meet specific technical and safety requirements. This reduces dependency on individual partners and allows the supply chain to be built flexibly in different countries.
Operational scalability is based on a model where users do not book appointments but are automatically connected to the first available doctor. This minimizes capacity constraints and allows the doctor network to grow progressively as market demand increases.
Omply also does not require significant operational changes from local healthcare providers. Doctors can conduct consultations from their own offices, and households use the service via their own smartphones. This enables very rapid market launches and extremely low adoption barriers in each region.
Omply works across different patient groups, ages, and clinical scenarios. This versatility is essential for global scalability: the service is not limited to a single disease area or use case but is suitable for acute symptoms, chronic condition monitoring, and everyday family healthcare needs.
Together, these elements form a scalable whole that can be deployed rapidly, efficiently, and safely across many types of healthcare systems. Omply is designed to grow with the market and meet the global need for bringing real diagnostic capability directly into households.
Execution of the funding round
- Target group: Existing shareholders (41) and new investors.
- Target amount to be raised: EUR 1,500,000 – 2,500,000
- Valuation: The current pre-money valuation of the Company is EUR 11.0 million (EUR 10 999 478,04).
- Timing: The share issue will be carried out from 11 December 2025 to 31 March 2026. However, the round may be closed earlier once fully subscribed. The sister company 73Health Oy’s share issue was oversubscribed in record time in spring 2025, and a similar outcome is expected for this round.
- Current number of shares: 43,135,208. Valuation per share: EUR 0.255.
- Shares offered: A minimum of 12.0% (5,882,353 shares) and a maximum of 18.5% (9,803,921 shares).
- Total shares after the round: 49,017,561 – 52,939,129.
- Minimum investment: EUR 15,000.12, corresponding to 58,824 shares, approx. 0.10–0.11% ownership depending on final subscription volumes.
- Eligible subscribers: Organisations and private individuals.
- No subscriber-specific restrictions.
- Investors must submit a binding electronic subscription notice and pay the share capital.
- The Board approves all subscriptions.
- New shareholders must electronically sign the shareholders’ agreement, which ensures equal treatment of all shareholders, as well as the Business Finland Co-Investment Fund (Innovestor Co-Investment Fund) supplementary details. The fund is one of the Company’s owners and conducted a full legal due diligence process through the law firm Byro Legal prior to the spin-off that established Omply Health as a separate B2C company.
Committed leadership
The Company has a professional Board of Directors, a Global Leadership Team, an experienced CEO, and a world-class team of experts. Personnel are located in Finland, Denmark, Canada, China, Zambia, and Pakistan.
Exit strategy
Shareholders aim to complete an exit within 4–5 years, with a target valuation of EUR 1 billion (~100x return on invested capital). Strategic acquisitions are possible, and a public listing may also be considered.
Next funding round
The Board estimates that the next investment round will take place in spring 2027 at a significantly higher valuation. In simple terms: if you believe in the Company, now is the right time to participate in the open round.
Take the
next step
At Omply, we believe care should be closer to people, and now is the time to make that a reality.
If you would like to learn more about the investment opportunity, the technology, or where we are headed, leave your contact details here or book a meeting to get in touch with us.